JP6959229B2 - 一本鎖ｇｉｔｒ受容体アゴニストタンパク質 - Google Patents

一本鎖ｇｉｔｒ受容体アゴニストタンパク質 Download PDF

Info

Publication number
JP6959229B2
JP6959229B2 JP2018521289A JP2018521289A JP6959229B2 JP 6959229 B2 JP6959229 B2 JP 6959229B2 JP 2018521289 A JP2018521289 A JP 2018521289A JP 2018521289 A JP2018521289 A JP 2018521289A JP 6959229 B2 JP6959229 B2 JP 6959229B2
Authority
JP
Japan
Prior art keywords
seq
gitrl
domain
receptor agonist
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018521289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501631A (ja
JP2019501631A5 (enExample
Inventor
クリスティアン・ギーフェルス
オリヴァー・ヒル
マイノルフ・ティーマン
ティム・シュニーダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Publication of JP2019501631A publication Critical patent/JP2019501631A/ja
Publication of JP2019501631A5 publication Critical patent/JP2019501631A5/ja
Application granted granted Critical
Publication of JP6959229B2 publication Critical patent/JP6959229B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
JP2018521289A 2015-10-23 2016-10-24 一本鎖ｇｉｔｒ受容体アゴニストタンパク質 Expired - Fee Related JP6959229B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245815P 2015-10-23 2015-10-23
US62/245,815 2015-10-23
PCT/EP2016/075552 WO2017068185A1 (en) 2015-10-23 2016-10-24 Single-chain gitr-receptor agonist proteins

Publications (3)

Publication Number Publication Date
JP2019501631A JP2019501631A (ja) 2019-01-24
JP2019501631A5 JP2019501631A5 (enExample) 2019-12-05
JP6959229B2 true JP6959229B2 (ja) 2021-11-02

Family

ID=57241058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521289A Expired - Fee Related JP6959229B2 (ja) 2015-10-23 2016-10-24 一本鎖ｇｉｔｒ受容体アゴニストタンパク質

Country Status (7)

Country Link
US (2) US10533043B2 (enExample)
EP (1) EP3365363A1 (enExample)
JP (1) JP6959229B2 (enExample)
CN (1) CN108473549A (enExample)
AU (1) AU2016341402B2 (enExample)
CA (1) CA3002741A1 (enExample)
WO (1) WO2017068185A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP7274426B2 (ja) 2017-05-16 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｇｉｔｒアゴニスト抗体での癌の処置
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775422B2 (en) * 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
PL202057B1 (pl) 1998-08-25 2009-05-29 Merck Patent Gmbh Homodimeryczne białko fuzyjne będące inhibitorem angiogenezy, sposób jego otrzymywania oraz cząsteczka DNA i wektor ekspresyjny zawierający to DNA
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
DE10122140A1 (de) * 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
ES2354954T3 (es) * 2006-03-22 2011-03-21 Viral Logic Systems Technology Corp. Métodos para identificar dianas polipeptídicas.
JP5283104B2 (ja) * 2007-01-10 2013-09-04 独立行政法人理化学研究所 アセチル化及び脱アセチル化の蛍光可視化検出方法
JP2010518140A (ja) * 2007-02-14 2010-05-27 グラクソ グループ リミテッド Ｉｇｆ−１ｒに対する新規抗体
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
WO2009016164A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
CN102250250A (zh) * 2011-07-09 2011-11-23 浙江大学 一种人鼠嵌合型抗人CD19抗体Hm2E8b及用途
WO2013092998A1 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
NO2776305T3 (enExample) * 2014-04-23 2018-01-27
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質

Also Published As

Publication number Publication date
CN108473549A (zh) 2018-08-31
AU2016341402B2 (en) 2020-08-27
US20200123223A1 (en) 2020-04-23
US20180244752A1 (en) 2018-08-30
AU2016341402A1 (en) 2018-05-10
WO2017068185A1 (en) 2017-04-27
US11149075B2 (en) 2021-10-19
US10533043B2 (en) 2020-01-14
EP3365363A1 (en) 2018-08-29
JP2019501631A (ja) 2019-01-24
CA3002741A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
JP6738831B2 (ja) 単鎖ｃｄ４０受容体アゴニストタンパク質
JP7033062B2 (ja) 一本鎖ｃｄ１３７受容体アゴニストタンパク質
JP6917368B2 (ja) 一本鎖ｃｄ２７受容体アゴニストタンパク質
JP6873119B2 (ja) 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
US11149075B2 (en) Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
US20180230196A1 (en) Single-chain ox40-receptor agonist proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211007

R150 Certificate of patent or registration of utility model

Ref document number: 6959229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees